OOIR: Observatory of International Research

Papers

(The H4-Index of Biodrugs is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Clinical Features and Drug Retention of TNF Inhibitors in Older Patients with Ankylosing Spondylitis: Results from the KOBIO Registry	292
Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond	215
Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis	103
Emerging Therapy in Osteoarthritis: Mesenchymal Stem Cells, Secretomes, and Using Hydrogels to Enhance Efficacy	102
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome	83
Modification of Extracellular Vesicle Surfaces: An Approach for Targeted Drug Delivery	78
Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor	75
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis	64
New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making	60
In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart	50
Historical Overview of Regulatory Approvals and PMDA Assessments for Biosimilar Products in Japan During 2009–2022	46
Acknowledgement to Referees	43
CAR-T Cells and the Kidney: Insights from the WHO Safety Database	42
Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials	39
A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?	35
Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic	33
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies	33
Correction to: Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy	32
Cell Engineering for Increasing Production of Recombinant Proteins in Mammalian Cells	30
Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective?	30
The Present and Future of Monoclonal Antibody Therapies for Multiple Sclerosis	30
First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data	29
Correction: Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review	29
Characterization of Biosimilar Monoclonal Antibodies and Their Reference Products Approved in Japan to Reveal the Quality Characteristics in Post-approval Phase	28
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?	27

Progress and Challenges in the Treatment of Fabry Disease	27
Malaria Vaccines: Progress to Date	27